Products Categories
| CAS No.: | 9067-32-7 |
|---|---|
| Name: | Hyaluronicacid, sodium salt |
| Article Data: | 2 |
| Cas Database | |
| Molecular Structure: | |
|
|
|
| Formula: | (C14H20NO11Na)n |
| Molecular Weight: | N/A |
| Synonyms: | Arthrease;Artz Dispo;Artzal;Bio Hyaluro 12;Chlamyhyaluronic acid sodium salt;Cystistat;FCH 121-S;FCH 200;FCH 248;FCH 60;FCH 80;FCH-SU;Fermatron;HA-F;HA-Q;HA-Q 1;HA-QA;Hyaluronate sodium inj;Hyaluronate sodium;HE-QSE;Healon;Healon (polysaccharide);Healon GV;Healon V;Hyalart;Hyalein;Hyalgan;Hyaluronsan HA-LQ;Hyaluronsan HA-LQ1;Hyaluronsan HA-LQH;Hyaluronsan HA-Q;Hyaluronsan HA-QSS;Hyaluronsan M 5070;Hyasol;Hyasol BT;Hyladerm;Khionat;NRD 101;Nidelon;Opegan;Orthovisc;Ostenil;Provisc;SI 4402;SL 1010;SLM 10;SPH;Sinovial;Sodium hyaluronate;Suvenyl; |
| EINECS: | 232-678-0 |
| Density: | 1.78g/cm3 |
| Melting Point: | N/A |
| Boiling Point: | 791.6oC |
| Flash Point: | 432.5oC |
| Solubility: | soluble in water |
| Appearance: | solid |
| Hazard Symbols: | B,Xi |
| Risk Codes: | 36/37/38 |
| Safety: | 22-24/25 |
| Transport Information: | N/A |
| PSA: | 399.71000 |
| LogP: | -8.49480 |
Please post your buying leads,so that our qualified suppliers will soon
contact you!
*Required Fields
Sodium hyaluronate is the sodium salt of hyaluronan. With the CAS NO. 9067-32-7, it is a visco-elastic polymer normally found in the aqueous and vitreous humour. It is also called Arthrease, Bio Hyaluro 12 , CCRIS 4127, Chlamyhyaluronic acid sodium salt. Sodium hyaluronate is a viscous solution consisting of a high molecular weight (500,000-730,000 daltons) fraction of purified natural sodium hyaluronate in buffered physiological sodium chloride. We should keep container tightly closed and keep container in a cool, well-ventilated area. Do not store above 8°C (46.4°F). Refrigerate. Store at tempertures from 2 - 8 °C.
Physical properties about Sodium hyaluronate are: (1)ACD/LogP: -1.131; (2)# of Rule of 5 Violations: 2; (3)ACD/LogD (pH 5.5): -3.85; (4)ACD/LogD (pH 7.4): -4.83; (5)ACD/BCF (pH 5.5): 1.00; (6)ACD/BCF (pH 7.4): 1.00; (7)ACD/KOC (pH 5.5): 1.00; (8)ACD/KOC (pH 7.4): 1.00; (9)#H bond acceptors: 12; (10)#H bond donors: 7; (11)#Freely Rotating Bonds: 10; (12)Flash Point: 432.5 °C; (13)Enthalpy of Vaporization: 131.19 kJ/mol; (14)Boiling Point: 791.6 °C at 760 mmHg; (15)Vapour Pressure: 5.77E-29 mmHg at 25°C
Uses of Sodium hyaluronate: Sodium hyaluronate is used as a viscosupplement, administered through a series of injections into the knee, increasing the viscosity of the synovial fluid, which helps lubricate, cushion and reduce pain in the joint. It is generally used as a last resort before surgery and provides symptomatic relief, by recovering the viscoelasticity of the articular fluid, and by stimulating new production from synovial fluid.
When you are using Sodium hyaluronate, please be cautious about it as the following:
1. Do not breathe dust;
2. Avoid contact with skin and eyes;
3. Wear suitable protective clothing, gloves and eye/face protection;
4. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice;
5. Take off immediately all contaminated clothing;
You can still convert the following datas into molecular structure:
(1)InChI=1S/C28H44N2O23.Na/c1-5(33)29-9-18(11(35)7(3-31)47-25(9)46)49-28-17(41)15(39)20(22(53-28)24(44)45)51-26-10(30-6(2)34)19(12(36)8(4-32)48-26)50-27-16(40)13(37)14(38)21(52-27)23(42)43;/h7-22,25-28,31-32,35-41,46H,3-4H2,1-2H3,(H,29,33)(H,30,34)(H,42,43)(H,44,45);/q;+1/t7-,8-,9-,10-,11-,12-,13+,14+,15-,16-,17-,18-,19-,20+,21+,22+,25-,26+,27-,28-;/m1./s1;
(2)InChIKey=YWIVKILSMZOHHF-QJZPQSOGSA-N;
(3)Smiles[Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1O[C@@H]1O[C@@H]([C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@@H](O[C@@H]3O[C@@H]([C@@H](O)[C@@H](O)[C@H]3O)C(O)=O)[C@H]2NC(C)=O)[C@@H](O)[C@H]1O)C(O)=O;
The toxicity data is as follows:
Organism Test Type Route Reported Dose (Normalized Dose) Effect Source dog LD50 subcutaneous > 50mg/kg (50mg/kg) GASTROINTESTINAL: NAUSEA OR VOMITING
SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 19(Suppl, mouse LD50 intraperitoneal 1500mg/kg (1500mg/kg) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
LUNGS, THORAX, OR RESPIRATION: DYSPNEA
SKIN AND APPENDAGES (SKIN): HAIR: OTHEROyo Yakuri. Pharmacometrics. Vol. 28, Pg. 1013, 1984. mouse LD50 oral > 2400mg/kg (2400mg/kg) Drugs in Japan Vol. -, Pg. 849, 1990. mouse LD50 subcutaneous > 4gm/kg (4000mg/kg) BEHAVIORAL: ATAXIA Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 12, Pg. 5369, 1984. rabbit LD50 intraperitoneal 1820mg/kg (1820mg/kg) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION
BLOOD: NORMOCYTIC ANEMIAYakuri to Chiryo. Pharmacology and Therapeutics. Vol. 12, Pg. 5369, 1984. rabbit LD50 oral > 1gm/kg (1000mg/kg) Drugs in Japan Vol. -, Pg. 849, 1990. rabbit LD50 subcutaneous > 2gm/kg (2000mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 12, Pg. 5369, 1984. rabbit LD50 subcutaneous > 2gm/kg (2000mg/kg) SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 12, Pg. 5369, 1984. rat LD50 intraperitoneal 1770mg/kg (1770mg/kg) SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE
BLOOD: NORMOCYTIC ANEMIAYakuri to Chiryo. Pharmacology and Therapeutics. Vol. 12, Pg. 5369, 1984. rat LD50 oral > 800mg/kg (800mg/kg) Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 12, Pg. 5369, 1984. rat LD50 subcutaneous > 4gm/kg (4000mg/kg) BEHAVIORAL: ATAXIA Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 12, Pg. 5369, 1984.
